16 September 2026 editorial review · Item
Rezpegaldesleukin (NKTR-358 / RESET T1D): review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Preventing and curing evidence review — 16 September 2026
- Disposition: new record; substantive review 16 September 2026.
- Scope and findings: Added a specific NKTR-358/RESET entry rather than treating the broad low-dose IL-2 item as equivalent. Checked current trial age-staging, target enrolment, dosing, status and dates; developer page supports proposed mechanism only.
- Primary sources checked: NCT07142252 — study record (registry); Nektar pipeline: rezpegaldesleukin in type 1 diabetes (manufacturer).
- Limits: No posted T1D outcomes. Dermatology efficacy and safety are not transferred to diabetes. Current site and individual age-cohort openings require confirmation.